
Occam continues its track record of company building with the placement of Nick Pullen, PhD as CSO of ARTBIO, a clinical-stage radiopharmaceutical play developing a new class of targeted alpha radioligand therapies. Pullen will join forces with Emanuele Ostuni, the CEO, whom Occam also placed last year.
Pullen brings over 20 years of leadership experience in the biopharmaceutical space and has led drug discovery programs spanning multiple gene classes, modalities and indications, including oncology, neuroscience and immunology. Prior to joining ARTBIO, Pullen served as SVP and Head of Research at Jnana. There he participated in their Series B and C fundraisings that together raised >$150 million; led a multi-target partnership with Roche; built a discovery pipeline; and put into development a first-in-class SLC6A19 allosteric inhibitor for the treatment of PKU. Before Jnana, Pullen was Vice President of Integrative Sciences at Celgene/BMS, and prior to that, he worked at Pfizer in several scientific leadership positions. Across both companies, Pullen was responsible for scientific and strategic leadership for many drug discovery programs.
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.